MAINZ BIOMED NV (MYNZ) Stock Overview
NASDAQ:MYNZ - NL0015000LC2 - Common Stock
MYNZ Key Statistics, Chart & Performance
The current stock price of MYNZ is 1.68 USD. In the past month the price increased by 26.32%. In the past year, price decreased by -88.13%.
MYNZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About MYNZ
Company Profile
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 19 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Company Info
MAINZ BIOMED NV
Sirius Gutenberg Park, Robert-Koch-Strasse 50
MAINZ HESSEN DE
Employees: 23
Phone: 4961315542860
MAINZ BIOMED NV / MYNZ FAQ
What is the stock price of MAINZ BIOMED NV today?
The current stock price of MYNZ is 1.68 USD. The price increased by 1.82% in the last trading session.
What is the ticker symbol for MAINZ BIOMED NV stock?
The exchange symbol of MAINZ BIOMED NV is MYNZ and it is listed on the Nasdaq exchange.
On which exchange is MYNZ stock listed?
MYNZ stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MAINZ BIOMED NV stock?
7 analysts have analysed MYNZ and the average price target is 14.28 USD. This implies a price increase of 750% is expected in the next year compared to the current price of 1.68. Check the MAINZ BIOMED NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MAINZ BIOMED NV worth?
MAINZ BIOMED NV (MYNZ) has a market capitalization of 7.69M USD. This makes MYNZ a Nano Cap stock.
How many employees does MAINZ BIOMED NV have?
MAINZ BIOMED NV (MYNZ) currently has 23 employees.
What are the support and resistance levels for MAINZ BIOMED NV (MYNZ) stock?
MAINZ BIOMED NV (MYNZ) has a support level at 1.63 and a resistance level at 1.81. Check the full technical report for a detailed analysis of MYNZ support and resistance levels.
Is MAINZ BIOMED NV (MYNZ) expected to grow?
The Revenue of MAINZ BIOMED NV (MYNZ) is expected to grow by 4.06% in the next year. Check the estimates tab for more information on the MYNZ EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MAINZ BIOMED NV (MYNZ) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MYNZ, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MYNZ, evaluating the profitability, health, valuation and growth aspects
- MAINZ BIOMED NV (MYNZ) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MAINZ BIOMED NV (MYNZ) Sales and EPS estimates to see what analysts future expectations are.
- MAINZ BIOMED NV (MYNZ) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MAINZ BIOMED NV (MYNZ) Insider and Institutional Ownership to learn about the owners and their transactions.
- MAINZ BIOMED NV (MYNZ) Stock Chart to make your own analysis
- MAINZ BIOMED NV (MYNZ) Latest news and press-releases to stay up to date.
Does MAINZ BIOMED NV (MYNZ) stock pay dividends?
MYNZ does not pay a dividend.
When does MAINZ BIOMED NV (MYNZ) report earnings?
MAINZ BIOMED NV (MYNZ) will report earnings on 2025-09-08.
What is the Price/Earnings (PE) ratio of MAINZ BIOMED NV (MYNZ)?
MAINZ BIOMED NV (MYNZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-22.72).
What is the Short Interest ratio of MAINZ BIOMED NV (MYNZ) stock?
The outstanding short interest for MAINZ BIOMED NV (MYNZ) is 2.33% of its float. Check the ownership tab for more information on the MYNZ short interest.
MYNZ Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MYNZ. When comparing the yearly performance of all stocks, MYNZ is a bad performer in the overall market: 97.46% of all stocks are doing better.
MYNZ Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MYNZ. MYNZ has a bad profitability rating. Also its financial health evaluation is rather negative.
MYNZ Financial Highlights
Over the last trailing twelve months MYNZ reported a non-GAAP Earnings per Share(EPS) of -22.72. The EPS increased by 64.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -169.23% | ||
| ROE | -363.64% | ||
| Debt/Equity | 0.14 |
MYNZ Forecast & Estimates
7 analysts have analysed MYNZ and the average price target is 14.28 USD. This implies a price increase of 750% is expected in the next year compared to the current price of 1.68.
For the next year, analysts expect an EPS growth of 77.35% and a revenue growth 4.06% for MYNZ